DexCom Stock Forecast, Price & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM shares have increased by 46.6% and is now trading at $370.12.
View which stocks have been most impacted by COVID-19.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom or view MarketBeat's top 5 stock picks.

Wall Street analysts have given DexCom a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DexCom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for DexCom.

DexCom will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom, Inc. (NASDAQ:DXCM) issued its earnings results on Tuesday, October, 27th. The medical device company reported $0.94 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.64 by $0.30. The medical device company earned $500.90 million during the quarter, compared to analyst estimates of $477.22 million. DexCom had a net margin of 12.69% and a trailing twelve-month return on equity of 27.29%.
View DexCom's earnings history.

DexCom issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $567 million, compared to the consensus revenue estimate of $550.73 million.

18 brokers have issued twelve-month price objectives for DexCom's shares. Their forecasts range from $240.00 to $500.00. On average, they anticipate DexCom's share price to reach $417.12 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for DexCom or view Wall Street analyst' top-rated stocks.

DexCom saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 3,490,000 shares, an increase of 19.9% from the December 15th total of 2,910,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is presently 3.1 days.
View DexCom's Short Interest.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all of DXCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a number of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.24%), Peregrine Capital Management LLC (0.11%), Scout Investments Inc. (0.05%), State of Alaska Department of Revenue (0.02%), Candriam Luxembourg S.C.A. (0.02%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Kovack Advisors Inc., Candriam Luxembourg S.C.A., State of Alaska Department of Revenue, Joel Isaacson & Co. LLC, Sowell Financial Services LLC, Gateway Investment Advisers LLC, and BKD Wealth Advisors LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom or view top insider-selling stocks.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Peregrine Capital Management LLC, Frontier Capital Management Co. LLC, Kestra Private Wealth Services LLC, Louisiana State Employees Retirement System, Exchange Traded Concepts LLC, Crossmark Global Holdings Inc., and Welch & Forbes LLC.
View insider buying and selling activity for DexCom or or view top insider-buying stocks.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $370.12.

DexCom has a market capitalization of $35.54 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]